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kind of dementia that causes problems with memory, thinking
and behavior. Symptoms typically develop slowly and become
worse over time, turning into severe enough to interfere with
daily tasks. Alzheimer’s disease (AD) represents for 60–80%
of dementia cases, but is not a normal part of aging although
the greatest known risk factor is increasing by age, and the
majority of people with AD are 65 years or older. However,
AD is not just a disease of old age. Up to 5% of people with
the disease have early onset AD (also known as younger-onset),
which often appears when someone is in their 40s or 50s [1].
AD typically progresses slowly in three general stages: mild
(early-stage), moderate (middle-stage), and severe (late-stage).
Since AD affects people in different ways, each person will
experience symptoms or progress through AD stages differ-
ently but early detection of symptoms is very important [2].
There is no specific test to prove the presence of AD with
absolute certainty. While physicians will nearly always confirm
if someone has dementia, it’s going to be tough to see the pre-
cise cause. Diagnosing AD needs careful medical evaluation,
including: a thorough medical history, mental status testing,
a physical and neurological exam and tests such as blood tests
and brain imaging to rule out other causes of dementia-like
symptoms [3].
The amyloid beta (Ab) hypothesis is recognized as the most
probable culpable for causing AD. Therefore, therapeutic
approaches based on the inhibition of amyloid aggregation
have been developed. But due to the difficulty of the design
of proteins or peptides similar to Ab peptide [1], many efforts
in this regard have failed. Although peptide or protein analogs
with specific binding sites might have the primary importance
for fundamental studies and diagnostics of the neurodegenera-
tive disorders, therapeutic agents have not been developed
within this strategy. Blood–brain barrier permeability, the
complexity of their synthesis, the low in vivo stability are some
of the problems. Also, the low efficacy of current regimens maybe attributed in part to the fact that these agents are designed
to bind to peptide monomers in a one to one ratio [4,5].
Nanoparticles with the unique properties can be good alter-
native for available treatments. Nowadays the applications of
nanoparticles as medicine have shown major successes in
different areas such as cancer therapy, diagnosis and etc.
Although many NPs are not biocompatible, they may be
considered as therapeutic agents because they are easy to syn-
thesize and have great in vivo stability. The biocompatibility of
many NPs may also be improved through coating techniques.
Many NPs can also penetrate the blood–brain barrier, which
further substantiates our interest in them in conjunction with
amyloid fibrillation in brain tissue [4].
On the other hand, all the methods of diagnosis, cannot
detect AD at earlier stages of the disease. As current treat-
ments will only postpone symptoms of AD, therefore, early
detection causes the physicians find the better treatments for
disease. Some of NPs such as gold NPs causes unique optical
properties [6]), that can be used as contrast agent for detection
of AD at the early stage. At early stage of AD, accumulation
of Ab monomer in the part of brain such as learning or think-
ing areas is increased. Therefore, this can be a path for the
detection of AD, as the binding of NPs to monomers may
result in the alteration of optical properties, hence resulting
in the detection of AD using MRI or other imaging methods.
It has recently been demonstrated that gold NPs inhibit
amyloid beta fibrillation process [6]. The protein adsorption
can lead to a decrease in the concentration of free amyloid
molecules in bulk and diminish the nucleation process which
represents the initial step in fibrillogenesis. Moreover, NPs
can bind to active sites. In this case, gold NPs have positive
surface charge that lead to their binding to amino acids with
negative charge such as Asp and Glu and hence blocking the
formation of the amyloid fibrils [6]. Therefore, gold NPs with
unique optical properties may be used for both early detection
and treatment simultaneously.
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good candidate for further studies to show if the use of gold
NPs will be beneficial for simultaneous early detection and
treatment of AD. In further studies NPs properties such as
composition, surface charge, shape, coating, size is very crucial
at this approach. Therefore, NPs must be characterized based
on all of these properties to obtain an effective therapy using
intelligent NPs for the early detection and treatment of AD.References
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